Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 28, 2025 07:00 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
September 13, 2024 07:00 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
May 21, 2024 07:15 ET | Source: SAB Biotherapeutics, Inc.

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
May 20, 2024 17:45 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

SAB Biotherapeutics Announces Q1 2024 Financial Results
May 06, 2024 07:15 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
April 16, 2024 07:15 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Provides SAB-142 Trial Update

SAB Biotherapeutics provides update on SAB-142 clinical trial for type 1 diabetes
April 08, 2024 07:15 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics to Present at INNODIA Annual Meeting

SAB Biotherapeutics, Inc. today announced their Chief Medical Officer will share an overview of the SAB-142 clinical development plan at INNODIA.